How Semaglutide Injections Work for Weight Loss

Last reviewed: June 2, 2026

Last updated: June 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide injections work by mimicking glucagon-like peptide-1 (GLP-1), a hormone that regulates appetite and blood sugar. In clinical trials, patients using semaglutide lost an average of 15-22% of body weight over 68 weeks, making it one of the most studied weight-loss medications available.

While the mechanism is well-established, individual response to semaglutide varies significantly. Genetic factors affecting GLP-1 receptor sensitivity and metabolic pathways may influence how your body responds to treatment, making personalized assessment valuable for optimizing your weight-loss strategy.

The GLP-1 Receptor: How Semaglutide Activates the Weight-Loss Pathway

Semaglutide is a GLP-1 receptor agonist that binds to GLP-1 receptors located throughout your brain, gut, and pancreas. This activation triggers a cascade of signals that suppress hunger hormones, increase satiety, and reduce food cravings—the primary mechanisms behind weight loss.

The medication also slows gastric emptying, meaning food stays in your stomach longer, creating prolonged feelings of fullness. Additionally, semaglutide enhances insulin secretion in response to meals and improves how your body uses glucose, contributing to metabolic benefits beyond weight reduction.

Pharmacokinetics and Clinical Efficacy: What Research Shows

Semaglutide reaches peak blood levels 1-3 days after injection and has a half-life of approximately 7 days, allowing once-weekly dosing. Clinical trials demonstrate dose-dependent weight loss: patients on 2.4 mg weekly achieved the most significant reductions compared to lower doses or placebo.

Study Parameter	Key Finding
STEP 4 Trial Weight Loss	Average 17.3% body weight reduction at 68 weeks
Dose Frequency	Once-weekly subcutaneous injection maintains therapeutic levels
Time to Peak Levels	1-3 days post-injection with 7-day half-life
Cardiovascular Benefit	Reduced major adverse cardiac events in LEADER trial
Appetite Reduction	60-70% of patients report significant hunger suppression

Individual Response Variation: Why Some Patients Lose More Weight Than Others

Not all patients achieve the same weight-loss results on semaglutide. Baseline metabolic rate, insulin resistance, genetic variations in GLP-1 receptor expression, and lifestyle factors significantly influence individual response. Understanding these factors helps explain why dose optimization or medication adjustment may be necessary.

Recent research suggests that variations in the GLP1R gene and related metabolic pathways, such as the GIPR and FTO genes, may predispose some individuals to stronger or weaker appetite suppression and weight-loss response. A targeted genetic assessment can reveal these predispositions and inform treatment planning.

Safety Considerations and Who Benefits Most from Semaglutide Treatment

Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Common side effects include nausea, vomiting, and diarrhea, typically mild and transient during the dose-escalation phase. Serious but rare risks include pancreatitis and gallbladder issues.

Treatment is most effective for individuals with a BMI of 30 or higher, or BMI of 27 with weight-related health conditions. However, not every patient tolerates semaglutide well, and genetic or metabolic factors may predict both tolerance and efficacy. A qualified healthcare provider should evaluate your eligibility and monitor your response throughout treatment.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test reveals predispositions in key GLP-1 and metabolic pathways, including GLP1R rs6923761, GIPR rs1800437, and FTO rs9939609 variants. These insights may help provide context for your expected semaglutide response and can support a more informed conversation with your provider about dosing strategy and realistic outcome expectations.

The genetic test does not predict your exact medication response or guarantee outcomes. Instead, it reveals predispositions that, when combined with your medical history and lifestyle factors, can help your provider personalize your treatment plan. Some individuals with certain GLP1R variants may require higher doses or longer adjustment periods to achieve optimal appetite suppression.

Understanding your genetic predispositions in semaglutide response pathways empowers you and your provider to set realistic goals, anticipate potential side effects, and adjust your treatment plan proactively. This personalization approach moves beyond a standard dose ladder toward true precision wellness.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.